Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: A phase II randomized study

Annals of Oncology

Volumn 21, Issue 7, 2009, Pages 1515-1522

  Paccagnella, A ^a   Ghi, M G ^a   Loreggian, L ^b   Buffoli, A ^c   Koussis, H ^b   Mione, C A ^d   Bonetti, A ^e   Campostrini, F ^f   Gardani, G ^g   Ardizzoia, A ^g   Dondi, D ^h   Guaraldi, M ⁱ   Cavallo, R ^j   Tomio, L ^k   Gava, A ^l  

^a Department of Medical Oncology ^*  (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^c Azienda Ospedaliera Universitaria   (Italy)

^d Ospedale SS Giovanni e Paolo   (Italy)

^e Departments of Medical Oncology   (Italy)

^f Ospedale Mater Salutis   (Italy)

^g SAN GERARDO HOSPITAL   (Italy)

^h Exploratory Unit   (Italy)

ⁱ UNIVERSITY OF BOLOGNA   (Italy)

^j P Cosma Hospital   (Italy)

^k SANTA CHIARA HOSPITAL   (Italy)

^l OSPEDALE CA FONCELLO   (Italy)

more..

Author keywords

Concomitant chemoradiotherapy; Head and neck cancer; Induction chemotherapy

Indexed keywords

ANTIEMETIC AGENT; CIPROFLOXACIN; CISPLATIN; DEXAMETHASONE; DOCETAXEL; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DYSPHAGIA; ENTERIC FEEDING; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; HEAD AND NECK CANCER; HUMAN; HUMAN TISSUE; HYDRATION; INFECTION; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NECK DISSECTION; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; SKIN TOXICITY; STOMATITIS; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; FEASIBILITY STUDIES; FEMALE; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; RADIOTHERAPY DOSAGE; REMISSION INDUCTION; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 77951477060     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp573     Document Type: Article

References (24)

1. Parkin DM, Bray F, Ferlay J et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Munrow AJ.. A systematic review of chemotherapy trials in head and neck cancer. Eur J Cancer 1999; 35 (Suppl 4/9): S602a.
3. Bernier J, Domenge C, Eschwege F et al. Chemo-radiotherapy, as compared to radiotherapy alone, significantly increases disease-free and overall survival in head and neck cancer patients after surgery: results of EORTC phase III trial 22931. N Engl J Med 2004; 350: 1937-1944.
4. Cooper SJ, Pajak TF, Forastiere AA et al. Patterns of failure for resected advanced head and neck cancer treated by concurrent chemotherapy and radiation therapy: an analysis of RTOG 9501/intergroup phase III trial. N Engl J Med 2004; 350: 1945-1952.
5. Pignon JP, Bouhris J, Domenge C et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000; 355: 949-955.
6. Wolf GT, Hong WK, Fisher SG et al. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1991; 324: 1685-1690.
7. Forastiere AA, Goepfert H, Maor M et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003; 349: 2091-2098.
8. Lefebvre JL, Chevalier D, Luboinski B et al. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. J Natl Cancer Inst 1996; 88: 890-899.
9. Hitt R, Ló pez-Pousa A, Martínez-Trufero J et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 2005; 23: 8636-8645.
10. Vermorken JB, Remenar E, Van Herpen C et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007; 357: 1695-1704.
11. Posner MR, Hershock DM, Blajman CR et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007; 357: 1705-1715.
12. Sobin LH, Wittekind C.. UICC TNM Classification of Malignant Tumours, 5th edition. New York, NY: Wiley-Liss 1997.
13. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
14. Brundage MD, Pater JL, Zee B. Assessing the reliability of two toxicity scales: implications for interpreting toxicity data. J Natl Cancer Inst 1993; 85: 1138-1148.
15. RTOG/EORTC. Late Radiation Morbidity Scoring Schema. http://www.rtog.org/members/toxicity/late.html (20 June 2008, date last accessed).
16. Simon R, Wittes RE, Ellenberg SS. Randomized phase II clinical trials. Cancer Treat Rep 1985; 69: 1375-1381.
17. Bourhis J, Le Maître A, Baujat B et al. Individual patients' data meta-analyses in head and neck cancer. Curr Opin Oncol 2007; 19: 188-194.
18. Paccagnella A, Orlando A, Marchiori C et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancer: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst 1994; 86: 265-272.
19. Zorat PL, Paccagnella A, Cavaniglia G et al. Randomized phase III trial of neoadjuvant chemotherapy in head and neck cancer: 10-year follow-up. J Natl Cancer Inst 2004; 96: 1714-1717.
20. Domenge C, Hill C, Lefebvre JL et al. Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'Etude des Tumeurs de la Tê te et du Cou (GETTEC). Br J Cancer 2000; 83: 1594-1598.
21. Bourhis J, Overgaard J, Audry H et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 2006; 368(9538): 843-854.
22. Ghi MG, Paccagnella A, D'Amanzo P et al. Neoadjuvant docetaxel, cisplatin, 5-fluorouracil before concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck versus concomitant chemoradiotherapy: a phase II feasibility study. Int J Radiat Oncol Biol Phys 2004; 59: 481-487.
23. Huguenin P, Beer KT, Allal A et al. Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancer treated with hyperfractionated radiotherapy. J Clin Oncol 2004; 22: 4665-4673.
24. Bonner J, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamouscell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-578.